RxDoctor Payments Data

Brooke Shadel, MD

Dermatology · Saint Louis, MONPI 1134327018

Payments from drug & device makers

$1,772in general payments, 2019–2025

Across 64 payments — averaging $27.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$645
  • Johnson & Johnson$354
  • Pfizer$166
  • AbbVie$158
  • Botanix SB Inc$138
  • Dermavant Sciences, Inc.$124
  • plus $188 from 7 others

What the payments were for

  • Food & beverage$1,36677%
  • Education$40623%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,772 in reported general payments places this provider in the 30th percentile of 263 dermatology providers in Missouri.

See all dermatology providers in Missouri

Medicare billing

Part B allowed, 2024
$227,212
Medicare patients
828
Services billed
3,717

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast13$31,842
Fluorouracil72$4,912
Calcipotriene32$3,327
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc47$2,959
Metronidazole58$2,768
Tacrolimus24$2,188
Ketoconazole164$1,976
Fluocinonide77$1,873
Nystatin76$1,353
Econazole Nitrate41$1,221
Clobetasol Propionate43$1,185
Tretinoin14$842
Doxycycline Hyclate24$832
Clindamycin Phosphate34$765
Triamcinolone Acetonide110$461

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$15$31,84213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 263 dermatology providers in Missouri.

Other dermatology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →